Skip to main content
Log in

Jede Verordnung kritisch hinterfragen

PPIs in Deutschland: zu oft, zu lange, zu viel?

Prescription of PPI in Germany: too often, too long, too much?

  • FORTBILDUNG . SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Protonenpumpenhemmer (PPIs) gelten zwar als sichere Medikamente. Angesichts steigender Verordnungszahlen gewinnen aber auch kleinste Risiken an Bedeutung. Welche Nebenwirkungen sind gesichert? Auf was müssen Sie bei der Verordnung/beim Absetzen achten?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1

Literatur

  1. https://www.aerzteblatt.de/nachrichten/87053/Aerzte-verordnen-weniger-Protonenpumpenhemmer

  2. Kelly WD, Hanners RE, Lockwood SM: Implementation of a proton pump inhibitor stewardship program. American Journal of Health-System Pharmacy June 2017,74:932–937

    Article  Google Scholar 

  3. Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann CJ, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth M. S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease. Z Gastroenterol. 2016; 54: 327–363

    Article  CAS  PubMed  Google Scholar 

  4. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80–7

    Article  CAS  PubMed  Google Scholar 

  5. Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;6:625–30.

    Article  Google Scholar 

  6. Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernandez C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician 2017;63:354–64.

    PubMed  PubMed Central  Google Scholar 

Weiterführende Literatur

  • Gaude GS. Pulmonary manifestations of gastroesophageal reflux disease. Ann Thorac Med 2009;4:115–123.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.

    Article  PubMed  PubMed Central  Google Scholar 

  • Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016;355:i5813

    Article  PubMed  PubMed Central  Google Scholar 

  • Targownik LE1, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010 Mar;138(3):896–904

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Manfred Gross.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gross, M., Labenz, J. PPIs in Deutschland: zu oft, zu lange, zu viel?. MMW - Fortschritte der Medizin 160, 37–40 (2018). https://doi.org/10.1007/s15006-018-0148-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-018-0148-2

Keywords

Navigation